Home/Pipeline/OPN-FMRP

OPN-FMRP

Solid Tumors

ResearchActive

Key Facts

Indication

Solid Tumors

Phase

Research

Status

Active

Company

Opna Bio

About Opna Bio

Opna Bio is a private, clinical-stage oncology biotech founded in 2021, leveraging a deep scientific foundation in the Hallmarks of Cancer. The company's strategy centers on designing small molecule inhibitors and degraders with differentiated pharmacokinetic profiles, such as 'pulsatile dosing,' to improve safety and efficacy. Its most advanced assets, the BET inhibitor zavabresib (OPN-2853) and the EP300 inhibitor OPN-6602, are in early-stage clinical trials for myelofibrosis and multiple myeloma, respectively. The leadership team, including co-founder and CSO Gideon Bollag, has a proven track record of advancing multiple drugs to FDA approval.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed